Würschmidt F, Bünemann H, Heilmann H P
Hermann-Holthusen-Institut für Strahlentherapie, Allgemeines Krankenhaus St. Georg, Hamburg.
Strahlenther Onkol. 1995 Jun;171(6):315-21.
Patients with malignant gliomas have a limited survival prognosis. We retrospectively analyzed data of malignant glioma patients with the aim of defining prognostic factors on which individualized treatment strategies might be built on.
Seventy-six patients with primary malignant glioma (51 glioblastoma multiforme, 20 anaplastic astrocytoma, 4 anaplastic oligo-astrocytoma, 1 anaplastic glioma) were postoperatively irradiated with 5 and 8 Me V photons, 2 Gy per fraction to a median total dose of 60 Gy (range 50 to 70 Gy).
The youngest quartile of patients (up to 45 years) had the highest 3-year survival rates (mean +/- SE: 15 +/- 8%) and median survival time (17.9 months, 95% confidence interval: 9.2, 24.2 months) as compared to the oldest quartile (> 61 years) with no 3-year survivor and a median survival time of 9.7 months (7.2, 12.3 months). The middle quartiles (46 to 61 years) showed intermediate results. The difference between the youngest and oldest quartile (p = 0.01) and the middle quartile versus the oldest quartile (p = 0.04) was significant. In univariate analysis, tumor size (p = 0.04 for -30 mm vs > 50 mm) was of importance. In multivariate analysis only age of the patient reached statistical significance (p = 0.03). As compared to the youngest quartile of patients, the oldest quartile had a relative risk of 2.1 (95% confidence interval: 0.9, 5.1) of dying from the disease; the age group of 46 to 61 years had a relative risk of 2.0 (0.9, 4.3).
Age of the patient is the most important factor for survival prognosis favouring younger age (< or = 45 years). The possible implications for radiation therapy are discussed.
恶性胶质瘤患者的生存预后有限。我们回顾性分析了恶性胶质瘤患者的数据,旨在确定可用于制定个体化治疗策略的预后因素。
76例原发性恶性胶质瘤患者(51例多形性胶质母细胞瘤、20例间变性星形细胞瘤、4例间变性少突星形细胞瘤、1例间变性胶质瘤)术后接受5和8兆电子伏光子照射,每次分割剂量2 Gy,中位总剂量60 Gy(范围50至70 Gy)。
最年轻的四分位数患者(45岁及以下)3年生存率最高(均值±标准误:15±8%),中位生存时间为17.9个月(95%置信区间:9.2,24.2个月);而最年长的四分位数患者(>61岁)无3年生存者,中位生存时间为9.7个月(7.2,12.3个月)。中间的四分位数患者(46至61岁)结果居中。最年轻与最年长四分位数患者之间的差异(p = 0.01)以及中间四分位数与最年长四分位数患者之间的差异(p = 0.04)具有统计学意义。单因素分析中,肿瘤大小具有重要性(-30 mm与>50 mm相比,p = 0.04)。多因素分析中,仅患者年龄达到统计学意义(p = 0.03)。与最年轻的四分位数患者相比,最年长的四分位数患者因该疾病死亡的相对风险为2.1(95%置信区间:0.9,5.1);46至61岁年龄组的相对风险为2.0(0.9, 4.3)。
患者年龄是生存预后的最重要因素,年龄较小(≤45岁)更具优势。文中讨论了对放射治疗的可能影响。